This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

The European FK 506 Multicentre Psoriasis Study Group

Arch Dermatol. 1996;132(4):419-423.

Abstract
Background and Design
Fifty patients with severe recalcitrant plaque-type psoriasis were randomized to receive treatment with either oral tacrolimus (FK 506) (n=27) or placebo (n=23) for 9 weeks. The two treatment groups were comparable with respect to baseline demographic data. The initial dose was 0.05 mg/kg per day and, in cases of insufficient efficacy, could be increased to 0.10 and 0.15 mg/kg per day at the end of weeks 3 and 6, respectively. Treatment efficacy was based on the percentage reduction in the Psoriasis Area and Severity Index compared with baseline data. Patients were defined as responding to therapy if the percentage change in the Psoriasis Area and Severity Index from baseline after 3, 6, and 9 weeks was 20% or greater, 45% or greater, and 70% or greater, respectively. Safety was assessed on the basis of all adverse events reported.

Results
At the end of week 9, tacrolimus-treated patients had a significantly greater reduction in the Psoriasis Area and Severity Index than did placebo-treated patients (tacrolimus, —83; placebo, —47; P<.02). Similar numbers of patients in both groups responded to therapy at the end of week 3, but at the end of weeks 6 and 9, more tacrolimus-treated patients responded to therapy (week 6, 12 tacrolimus- and six placebo-treated patients; week 9, 12 tacrolimus- and three placebo-treated patients). Diarrhea, paresthesia, and insomnia were the most frequently reported causally related adverse events in the tacrolimus-treated group. All of the reported adverse events were mild or moderate in severity, and all resolved without a change in study medication.

Conclusion
Compared with placebo, tacrolimus is efficacious in the treatment of recalcitrant plaque-type psoriasis.

(Arch Dermatol. 1996;132:419-423)

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Topical Tacrolimus Ointment Combined With 6% Salicylic Acid Gel for Plaque Psoriasis Treatment
Carroll et al.
Arch Dermatol 2005;141:43-46.
ABSTRACT | FULL TEXT  

The Course of Chronic Plaque-Type Psoriasis in Placebo Groups of Randomized Controlled Studies
Spuls et al.
Arch Dermatol 2004;140:338-344.
ABSTRACT | FULL TEXT  

A Case of Generalized Pustular Psoriasis Treated With Topical Tacrolimus
Ishiko et al.
Arch Dermatol 2003;139:1219-1219.
FULL TEXT  

Successful Treatment of Vulvar Lichen Sclerosus With Topical Tacrolimus
Kunstfeld et al.
Arch Dermatol 2003;139:850-852.
FULL TEXT  

Tacrolimus Ointment in the Treatment of Chronic Cutaneous Graft-vs-Host Disease: A Case Series of 18 Patients
Choi and Nghiem
Arch Dermatol 2001;137:1202-1206.
ABSTRACT | FULL TEXT  

Successful Treatment of Erosive Lichen Planus With Topical Tacrolimus
Lener et al.
Arch Dermatol 2001;137:419-422.
FULL TEXT  

Tacrolimus: The Drug for the Turn of the Millennium?
Ruzicka et al.
Arch Dermatol 1999;135:574-580.
ABSTRACT | FULL TEXT  

Topical Tacrolimus Is Not Effective in Chronic Plaque Psoriasis: A Pilot Study
Zonneveld et al.
Arch Dermatol 1998;134:1101-1102.
ABSTRACT | FULL TEXT  

A Short-Term Trial of Tacrolimus Ointment for Atopic Dermatitis
Ruzicka et al.
NEJM 1997;337:816-821.
ABSTRACT | FULL TEXT  

Tacrolimus for Severe Psoriasis
Journal Watch Dermatology 1996;1996:10-10.
FULL TEXT